JPRN-UMIN000028153
Completed
N/A
Clinical data over 24 months with dapagliflozin treatment for type 2 diabetes patients in our hospital - Clinical data over 24 months with dapagliflozin treatment for type 2 diabetes patients in our hospital
Conditionstype2 diabetes
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- type2 diabetes
- Sponsor
- Tokyo Medical University
- Enrollment
- 42
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients suspected of having secondary diabetes (ex. endocrine disease, drug\-induced or liver disease) 2\) Females who are pregnant or who intend to become pregnant within the study 3\) Severe hepatic disease, malignancy, a history of gastrectomy and/or positive for HIV 4\) Contraindication with dapagliflozin 5\) Patient who disqualified from the study by the investigator for any reason other than given above.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Patient Reported Outcome study of Dapagliflozin on glycemic control and treatment satisfaction in overweight patients with type 2 diabetes mellitusOverweight patients with type 2 diabetes mellitusJPRN-UMIN000016304Japan society for Patient Reported Outcome220
Not Yet Recruiting
N/A
Benefits and side effects of Dapagliflozin medicine in diabetic patients with kidney disease.CTRI/2022/09/045596Maulana Azad Medical College Delhi
Not Yet Recruiting
N/A
Dapagliflozin in Heart FailureCTRI/2022/11/047725Sanjay Kumar R
Recruiting
N/A
Examination of the efficacy of dapagliflozin in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000021954Tonami general hospital Department of diabetes mellitus and endocrinology200
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003897-41-PLAstraZeneca AB4,500